Royal Bank Of Canada Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

02 May 2026, 08:46 by Doug Wharley · The Cerbat Gem

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective cut by investment analysts at Royal Bank Of Canada from $779.00 to $762.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 8.64% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a research report on Thursday. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Evercore raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Finally, TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $826.59.

View Our Latest Report on REGN

Regeneron Pharmaceuticals Trading Down 0.8%

Shares of REGN opened at $701.42 on Thursday. The stock has a market capitalization of $74.15 billion, a P/E ratio of 17.09, a PEG ratio of 1.63 and a beta of 0.30. The company has a quick ratio of 3.39, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $756.81 and a two-hundred day simple moving average of $735.17. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $8.22 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals will post 35.98 EPS for the current year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 in the last three months. 7.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a “sector perform” stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today’s weaker price action. Regeneron drops despite Q1 beat

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.